Skip to main content
. 2021 Feb 3;11:2933. doi: 10.1038/s41598-021-82492-x

Table 3.

Radiologic, laboratory findings and complications.

Variables Patients (N = 659) ARDS patients (N = 76) Non-ARDS patients (N = 583) P value
CT image features—no./total no. (%)
Consolidation 175/619(28.3%) 41/76(53.9%) 134/543(24.7%) 0.000
Ground-glass opacity 467/625(74.7%) 59/73(80.8%) 408/552(73.9%) 0.251
Number of consolidation quadrant—Median (IQR) 0(0–2) 2(1–4) 0(0–2) 0.000
Laboratory findings
Leukocyte count within 48 h of admission (10e9/l)
 Median (IQR) 5.0(4.0–6.6) 5.7(4.6–8.8) 4.9(3.9–6.4) 0.000
 Distribution—no./total no. (%) 0.000
  < 4 163/657(24.8%) 14/76(18.4%) 149/581(25.6%)
 4–10 468/657(71.2%) 47/76(61.8%) 421/581(72.5%)
  > 10 26/657(4.0%) 15/76(19.7%) 11/581(1.9%)
Neutrophil count (10e9/l) -Median(IQR) 3.2(2.3–4.4) 4.8(3.1–7.6) 3.1(2.3–4.2) 0.000
Lymphocyte count (10e9/l)
 Median (IQR) 1.1(0.8–1.6) 0.7(0.5–1.1) 1.2(0.8–1.7) 0.000
 Distribution—no./total no. (%) 0.000
  ≤ 1.5 468/659(71.0%) 71/76(93.4%) 397/583(68.1%)
  > 1.5 191/659(29.0%) 5/76(6.6%) 186/583(31.9%)
Lymph%
 Median (IQR) 0.24(0.2–0.3) 0.13(0.1–0.2) 0.25(0.2–0.3) 0.403
 Distribution—no./total no. (%)
  < 0.2 237/657(36.1%) 56/76(73.7%) 181/581(31.2%) 0.000
  ≥ 0.2 420/657(63.9%) 20/76(26.3%) 400/581(68.8%)
Neutrophils / lymphocytes
 Median (IQR) 2.73(1.8–4.5) 6.11(3.7–14.6) 1.2(1.7–4.0) 0.000
 Distribution—no./total no. (%) 0.000
  < 3 348/636(54.7%) 13/75(17.3%) 335/561(59.7%)
  ≥ 3 288/636(45.3%) 62/75(82.7%) 226/561(40.3%)
Hemoglobin (g/l)- Median (IQR) 134.0(123.0–146.0) 135.5(123.3–150.0) 134(123.0–144.0) 0.462
Hematocrit (%)- Median (IQR) 0.4(0.0–0.4) 0.4(0.3–0.4) 0.39(0.4–0.5) 0.968
Platelet (10e9/l)
 Median (IQR) 195(152–243) 174(138–222) 197(154–243) 0.012
 Distribution—no./total no. (%) 0.509
  ≤ 100 24/658(3.6%) 4/76(5.3%) 20/582(3.4%)
  > 100 634/658(96.4%) 72/76(94.7%) 562/582(96.6%)
Alanine aminotransferase (U/L)
 Median (IQR) 21.0(15–34.0) 30.3(21.3–46.0) 20.0(14.0–32.0) 0.000
 Distribution—no./total no. (%) 0.000
  ≤ 40 533/654(81.5%) 48/74(64.9%) 485/580(83.6%)
  > 40 121/654(18.5%) 26/74(35.1%) 95/580(16.4%)
Aspartate aminotransferase (U/L)
 Median (IQR) 24.0(18.0–31.0) 31.5(24.0–46.0) 23(18.0–30.0) 0.000
 Distribution—no./total no. (%) 0.000
  ≤ 40 563/653(86.2%) 44/74(59.5%) 519/579(89.6%)
  > 40 90/653(13.8%) 30/74(40.5%) 60/579(10.4%)
Potassium ion (mmol/L)—median(IQR) 3.8(3.6–4.2) 3.8(3.5–4.1) 3.9(3.6–4.2) 0.188
Sodium ion (mmol/L)—median(IQR) 138.8(136.7–146.7) 138.0(135.0–140.6) 139.0(137.0–140.7) 0.052
Creatinine (umol/l)
 Median (IQR) 65.3(54.0–78.0) 70.5(59.5–92.0) 65.0(53.4–77.4) 0.002
 Distribution—no./total no. (%) 0.072
  ≤ 133 648/657(98.6%) 72/75(96.0%) 576/582(99.0%)
  > 133 9/657(1.4%) 3/75(4.0%) 6/582(1.0%)
Creatine Kinase (U/L)
 Median (IQR) 74.0(50.8–107.2) 112.5(63.0–245.0) 70.6(49.0–96.3) 0.000
 Distribution—no./total no. (%) 0.000
  ≤ 185 461/513(89.9%) 47/68(69.1%) 414/445(93.0%)
  > 185 52/513(10.1%) 21/68(30.9%) 31/445(7.0%)
Lactate dehydrogenase (U/L)
 Median (IQR) 215.0(177.0–275.3) 316.0(253.8–394.0) 211.0(173.5–257.5) 0.000
 Distribution—no./total no. (%) 0.000
  ≤ 250 431/636(67.8%) 17/69(24.6%) 414/567(73.0%)
  > 250 205/636(32.2%) 52/69(75.4%) 153/567(27.0%)
Troponin I (ng/ml—Median (IQR) 0.0(0.01–0.06) 0.0(0.00–0.03) 0.0(0.01–0.09) 0.013
Brain Natriuretic Peptide (< 300 pg/ml)—Median (IQR) 82.0(27–144.5) 77.0(36.0–164.0) 82.3(26.5–139.7) 0.566
Myoglobin—Median (IQR) 25.1(18.5–40.6) 85.9(43.2–205.9) 23.6(18.2–33.1) 0.000
Glucose (mmol/L)—Median (IQR) 5.9(5.1–7.7) 8.1(6.6–9.9) 5.7(5.1–7.4) 0.000
C-reactive protein (mg/L)
 Median (IQR) 10(3.0–27.3) 34.1(15.3–76.0) 8.8(2.8–24.1) 0.000
 Distribution—no./total no. (%) 0.000
  ≤ 10 341/648(52.6%) 14/73(19.2%) 327/575(56.9%)
  > 10 307/648(47.4%) 59/73(80.8%) 248/575(43.1%)
Procalcitonin (ng/L)
 Median (IQR) 0.1(0.0–0.1) 0.1(0.1–0.2) 0.1(0.0–0.1) 0.008
 Distribution—no./total no. (%) 0.195
  < 0.1 326/510(63.9%) 37/68(54.4%) 289/442(65.4%)
 0.1–0.5 164/510(32.2%) 27/68(39.7%) 137/442(31.0%)
  ≥ 0.5 20/510(3.9%) 4/68(5.9%) 16/442(3.6%)
Highest CRP within one week of admission (mg/L)—Median (IQR) 15.5(4.0–39.6) 45.8(17.7–83.1) 12.2(3.8–34.2) 0.000
Highest PCT within one week of admission (ng/L)—Median (IQR) 0.1(0.0–0.1) 0.1(0.1–0.2) 0.1(0.0–0.1) 0.000
FiO2 on the first day of admission—Median (IQR) 0.3(0.2–0.3) 0.2(0.3–0.5) 0.3(0.2–0.3) 0.000
PaO2 on the first day of admission (mmHg)—Median (IQR) 90.7(78.0–111.0) 79.0(67.9–95.2) 94.0(80.2–117.0) 0.019
PaCO2 on the first day of admission (mmHg)—Median (IQR) 37.5(34.0–41.5) 33.0(32.4–37.5) 38.0(34.8–41.9) 0.699
Oxygenation index on the first day of admission (mmHg)
 Median (IQR) 292.2(144.4–424.3) 240(160.8–261.2) 352.0(64.2–466.2) 0.000
 Distribution—no./total no. (%) 0.000
  ≤ 200 106/325(32.6%) 35/69(50.7%) 71/256(27.7%)
  > 200 219/325(67.4%) 34/69(49.3%) 185/256(72.3%)
D-dimer (μg/L)—Median (IQR) 250.0(140.0–525.3) 819.0(276.0–1212.0) 238.0(130.0–458.0) 0.000
Complications—no./total no. (%)
Shock 4/647(0.6%) 4/73(5.5%) 0/574(0.0%) 0.000
Secondary bacterial infection 48/659(7.3%) 23/76(30.3%) 25/583(4.3%) 0.000

CT, computerized tomography; CRP, c-reactive protein; PCT, procalcitonin; no., number.

Data are presented as medians (interquartile ranges, IQR) and no./total no. (%).